RECENT Healthcare RESEARCH
On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.
Johnson & Johnson (JNJ) is set to release its 3Q17 earnings on October 17. Analysts expect JNJ’s 3Q17 revenues to rise ~8.3% to ~$19.3 billion compared to ~$17.8 billion for 3Q16.
Of the three analysts covering Sanofi in October 2017, two have rated the stock a “strong buy,” and one has rated it a “hold.”
Edwards Lifesciences (EW) has scheduled its 3Q17 earnings release for October 24, 2017. This leading player in the artificial heart valves market has been gaining momentum and trading near its 52-week high.
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
Johnson & Johnson (JNJ) will announce its 3Q17 earnings results on October 17, 2017.
Intuitive Surgical (ISRG) is set to announce its 3Q17 earnings results on October 19, 2017. Over the past few weeks, ISRG stock has risen to new highs.
On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.
Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ~$189.35.
In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.
Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn’t receive any “sell” or “strong sell” ratings.
Intuitive Surgical (ISRG), the leader in minimally invasive robotics surgery, has seen tremendous growth lately. It was trading at its 52-week high of $1,094.55 on October 5, 2017.
Of the 15 firms tracking BD, ~67% of analysts have recommended a “buy” for BD—of which 70% have given a “strong buy” recommendation.
Cardinal Health (CAH) reported revenues of $130.0 billion for fiscal 2017, which is a YoY (year-over-year) rise of 7.0%.
Ten analysts were covering Exelixis in October 2017. One analyst suggested a “strong buy,” and five analysts suggested a “buy” rating.
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals’ (ALXN) Soliris.
Rite Aid (RAD) reported results for 2Q17 on Thursday, September 28, 2017. The company reported a loss of one cent per share on total sales of $7.7 billion.
On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.
Abbott Laboratories (ABT) was trading at its 52-week high of $54.75 on September 29, 2017.
Medtronic (MDT) aims to leverage its expertise in implantable pump and electronics segments to further improve Heartware’s LVAD (left ventricular assist device) product portfolio.